Moventig

Moventig

Medication details

Moventig is indicated for the treatment of:

opioid-induced constipation (OIC) in adult patients whose response to laxatives was insufficient.

Definition of insufficient response to laxatives:

during the two weeks preceding the use of naloxegol, reporting OIO symptoms of at least moderate intensity, which persisted even after taking a laxative for at least 4 days.

Medication strengths and packagings

MOVENTIG 25MG TBL FLM 30X1

Strength: 25 mg
Packaging: 30X1

PDF with SmPC – see attachment

Reporting side effects

Any suspicion of a serious or unexpected effect and other actualities serious for the treated person's health must be reported to the State Institute for Drug Control (SÚKL).

Details on the report can be found at: www.sukl.cz/nahlasit-nezadouci-ucinek

Address for shipment is: Státní ústav pro kontrolu léčiv, oddělení farmakovigilance, Šrobárova 48, Praha 10, 100 41, e-mail: farmakovigilance@sukl.cz.

This information for Moventig medicament may also be reported to the company Pharma-Service International s.r.o., contact:

Publicly accessible information line (PAPIS)

The obligation to establish a Publicly Accessible Professional Information Service (PAPIS) result from Act No. 378/2007 Sb., O léčivech. Information on our products can be found on the website of the State Institute for Drug Control (SÚKL) in the drug database. Summaries of Product Characteristics can be found in the pdf. file by clicking on the Product name.

The Publicly Accessible Professional Information Service (PAPIS) for Moventig is operated by the marketing authorization holder - Pharma-Service International s.r.o., contact:

Medication details

Tags

Medication strengths and packagings

MOVENTIG 25MG TBL FLM 30X1

Reporting side effects

Publicly accessible information line (PAPIS)